Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 18Carcinoma, Hepatocellular 9Neoplasms 8Melanoma 7Squamous Cell Carcinoma of Head and Neck 6Nasopharyngeal Carcinoma 6Triple Negative Breast Neoplasms 5Esophageal Neoplasms 5Neoplasm Metastasis 4Esophageal Squamous Cell Carcinoma 4Colonic Neoplasms 4Recurrence 3Rectal Neoplasms 3Pancreatic Neoplasms 3Lung Neoplasms 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Stomach Neoplasms 2Solid Cancers 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Ovarian Neoplasms 2Gastric / Gastroesophageal Junction Adenocarcinoma 2EBV-associated Tumors 2Cholangiocarcinoma 2Breast Neoplasms 2Bites and Stings 2Biliary Tract Neoplasms 2Advanced Solid Tumors 2

Interventions

Cyclophosphamide 51fludarabine 37Dexamethasone 35venetoclax 30pembrolizumab 25Rituximab 20pomalidomide 18Lenalidomide 17Gemcitabine 17fludarabine phosphate 15Etoposide 14Cytarabine 13daratumumab 12carfilzomib 11Temozolomide 11Injections 10Calcium Dobesilate 10glofitamab 9Nivolumab 9Cisplatin 9Bortezomib 9Azacitidine 9selinexor 8Vincristine 8Immunotherapy, Adoptive 8obinutuzumab 7cemiplimab 7Drug Therapy 7Carboplatin 7zanubrutinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recurrence × Immune Checkpoint Inhibitors × 1 year × Clear all
NCT04539444 2026-06-02

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

The First Affiliated Hospital of Soochow University

Phase 2 Completed
18 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

NCT07277777 2026-01-06

125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors

Jinan Military General Hospital

Phase 2 Not yet recruiting
90 enrolled

Neoplasms, Recurrence

NCT07070479 2025-09-18

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Sun Yat-sen University

Phase 2 Recruiting
208 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡